| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005971A2 Secreted polypeptides and corresponding polynucleotides |
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005968A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/25/2001 | WO2001005967A1 Splice variants of cd40-receptor |
| 01/25/2001 | WO2001005966A1 Nucleic acids coding for peptides having the biological activity of sorbin |
| 01/25/2001 | WO2001005964A1 Inhibitor of osteoclast precursor formation |
| 01/25/2001 | WO2001005963A2 ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1) |
| 01/25/2001 | WO2001005958A1 Antisense modulation of p13 kinase p110 delta expression |
| 01/25/2001 | WO2001005947A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | WO2001005943A2 Lcat recombinant cell line compositions and methods |
| 01/25/2001 | WO2001005836A1 Polypeptidic compositions and methods for the treatment of tumors |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005833A1 Odorant receptors |
| 01/25/2001 | WO2001005831A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | WO2001005826A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | WO2001005823A2 Tryptase inhibitor |
| 01/25/2001 | WO2001005821A2 Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis |
| 01/25/2001 | WO2001005820A2 Method for down-regulating gdf-8 activity |
| 01/25/2001 | WO2001005819A1 Novel water soluble-cyclosporine conjugated compounds |
| 01/25/2001 | WO2001005818A1 Novel water soluble-cyclosporin conjugated compounds |
| 01/25/2001 | WO2001005817A1 Pseudomycin amide and ester analogs |
| 01/25/2001 | WO2001005816A1 Amine-modified pseudomycin compounds |
| 01/25/2001 | WO2001005815A1 Process for deacylation of lipodepsipeptides |
| 01/25/2001 | WO2001005814A1 Pseudomycin n-acyl side-chain analogs |
| 01/25/2001 | WO2001005813A1 Pseudomycin prodrugs |
| 01/25/2001 | WO2001005812A2 PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING α3β1 INTEGRINS |
| 01/25/2001 | WO2001005811A2 Cyclic peptidomimetic urokinase receptor antagonists |
| 01/25/2001 | WO2001005810A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6? |
| 01/25/2001 | WO2001005804A1 Novel genes associated with renal disease |
| 01/25/2001 | WO2001005803A1 NOVEL cDNAs ASSOCIATED WITH RENAL DISEASE |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005772A1 Pyrazinones, compositions containing such compounds |
| 01/25/2001 | WO2001005480A2 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 01/25/2001 | WO2001005443A1 Adhesive protein foam for surgical and/or therapeutic uses |
| 01/25/2001 | WO2001005435A2 Antisense therapy for hormone-regulated tumors |
| 01/25/2001 | WO2001005432A2 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 01/25/2001 | WO2001005427A1 Psca: prostate stem cell antigen and uses thereof |
| 01/25/2001 | WO2001005423A1 Use of vasoactive intestinal peptide (vip) for modulating the development of a specific immune response |
| 01/25/2001 | WO2001005422A2 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | WO2001005421A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells |
| 01/25/2001 | WO2001005420A1 Small peptides and methods for downregulation of ige |
| 01/25/2001 | WO2001005419A2 Agent for treating cardiac diseases |
| 01/25/2001 | WO2001005418A2 Tissue regenerating agent |
| 01/25/2001 | WO2001005414A1 Algae protein polysaccharide extraction and use thereof |
| 01/25/2001 | WO2001005410A1 Neurotropic virus transport |
| 01/25/2001 | WO2001005405A1 Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
| 01/25/2001 | WO2001005401A1 Melanocortin receptor-3 ligands to treat sexual dysfunction |
| 01/25/2001 | WO2001005383A2 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 01/25/2001 | WO2001005379A1 BIODEGRADABLE POLY(ALKYLENE OXIDE)-POLY(p-DIOXANONE) BLOCK COPOLYMER SOLUBLE IN ORGANIC SOLVENTS, AND DRUG DELIVERY COMPOSITION COMPRISING SAME |
| 01/25/2001 | WO2001005355A2 Formulations for il-11 |
| 01/25/2001 | WO2001005353A2 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 01/25/2001 | WO2001005222A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 01/25/2001 | WO2000071576A3 Adenovirus vectors encoding brain natriuretic peptide |
| 01/25/2001 | WO2000068399A3 Vector-mediated delivery of integrating transposon sequences |
| 01/25/2001 | WO2000068240A8 NOVEL aroA |
| 01/25/2001 | WO2000067739A3 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 01/25/2001 | WO2000066587A3 Polyamines and their use in therapy |
| 01/25/2001 | WO2000066550A8 New compounds |
| 01/25/2001 | WO2000064930A3 Tribonectins |
| 01/25/2001 | WO2000063357A3 Methods and compositions for modulating ciliary neurotrophic factor activity |
| 01/25/2001 | WO2000062805A8 A method of reversing thymic atrophy |
| 01/25/2001 | WO2000061176A3 Treatment of multiple sclerosis with a combination of interferon and growth hormone |
| 01/25/2001 | WO2000061174A3 Use of pegylated interferon alpha for renal cell carcinoma treatment |
| 01/25/2001 | WO2000061173A3 Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000060080A3 Molecules of the immune system |
| 01/25/2001 | WO2000059940A3 Platelet-derived growth factor related gene and protein |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000058465A3 Flint polypeptide analogs |
| 01/25/2001 | WO2000058360A3 Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
| 01/25/2001 | WO2000057837A3 Compositions and methods for effecting the levels of cholesterol |
| 01/25/2001 | WO2000053219A3 Compositions and methods for treating cancer and hyperproliferative disorders |
| 01/25/2001 | WO2000053211A3 Method of promoting myocyte proliferation and myocardial tissue repair |
| 01/25/2001 | WO2000047721A3 Methods of inducing insulin positive progenitor cells |
| 01/25/2001 | WO2000047605A3 Enterocyte growth factors and method for their isolation |
| 01/25/2001 | DE19934603A1 Regulatorisches Protein pKe#165 aus humanen Keratinozyten Regulatory protein pKe # 165 from human keratinocytes |
| 01/25/2001 | DE19934029A1 Preparing an agent for diagnosis or control of microbial infection, useful particularly against Helicobacter, based on identification of essential genes in defective mutants |
| 01/25/2001 | DE19933701A1 Zyklische peptidomimetische Urokinaserezeptorantagonisten Cyclic peptidomimetic Urokinaserezeptorantagonisten |
| 01/25/2001 | DE19930959A1 Neue Antimycotika und Fungizide, Verfahren zu deren Herstellung und Verwendung New antimycotics and fungicides, processes for their preparation and use |
| 01/25/2001 | CA2616704A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2381961A1 Splice variants of cd40-receptor |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2380000A1 Odorant receptors |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | CA2379968A1 Gtp-binding protein associated factors |
| 01/25/2001 | CA2379925A1 Polypeptides and polynucleotides encoding same |
| 01/25/2001 | CA2379852A1 Method for down-regulating gdf-8 activity |
| 01/25/2001 | CA2379851A1 Pseudomycin n-acyl side-chain analogs |
| 01/25/2001 | CA2379825A1 Nucleic acids coding for peptides having the biological activity of sorbin |
| 01/25/2001 | CA2379627A1 Inhibitor proteins |
| 01/25/2001 | CA2379618A1 Viral protein binding compositions and methods |
| 01/25/2001 | CA2379391A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | CA2379354A1 Formulations for il-115 |
| 01/25/2001 | CA2379336A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2379325A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells |
| 01/25/2001 | CA2379323A1 Small peptides and methods for downregulation of ige |
| 01/25/2001 | CA2379321A1 Pseudomycin amide and ester analogs |
| 01/25/2001 | CA2379317A1 Amine-modified pseudomycin compounds |